Chemed Corporation $CHE Stake Raised by Brogan Financial Inc.

Brogan Financial Inc. boosted its holdings in shares of Chemed Corporation (NYSE:CHE) by 57.0% in the second quarter, HoldingsChannel reports. The fund owned 669 shares of the company’s stock after buying an additional 243 shares during the quarter. Brogan Financial Inc.’s holdings in Chemed were worth $326,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Renasant Bank lifted its position in shares of Chemed by 2.3% in the first quarter. Renasant Bank now owns 815 shares of the company’s stock worth $501,000 after purchasing an additional 18 shares in the last quarter. Cim LLC increased its stake in Chemed by 1.0% in the 1st quarter. Cim LLC now owns 2,029 shares of the company’s stock valued at $1,248,000 after buying an additional 21 shares during the period. Cynosure Group LLC lifted its position in Chemed by 4.3% in the 1st quarter. Cynosure Group LLC now owns 581 shares of the company’s stock worth $358,000 after buying an additional 24 shares in the last quarter. Atria Investments Inc lifted its position in Chemed by 0.6% in the 2nd quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after buying an additional 25 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Chemed by 16.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 202 shares of the company’s stock valued at $99,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Performance

CHE opened at $447.18 on Thursday. The company has a market cap of $6.33 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. The stock has a 50-day moving average of $444.87 and a 200-day moving average of $485.34. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million during the quarter, compared to the consensus estimate of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $5.64 earnings per share. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, research analysts predict that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 12.69%.

Wall Street Analyst Weigh In

CHE has been the topic of a number of research reports. Bank of America dropped their price target on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Royal Bank Of Canada dropped their target price on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Oppenheimer lowered their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Finally, Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and increased their price objective for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $574.25.

Insider Activity at Chemed

In other news, Director Patrick P. Grace sold 150 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. The trade was a 4.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the sale, the chief executive officer directly owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This represents a 3.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.29% of the company’s stock.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.